1. Search Result
Search Result
Results for "

α-Syn

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

6

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-163145

    α-synuclein Neurological Disease
    α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research .
    α-Synuclein inhibitor 11
  • HY-157308

    α-synuclein Neurological Disease
    α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC50 value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .
    α-Synuclein inhibitor 10
  • HY-163519

    α-synuclein Neurological Disease
    α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .
    α-Synuclein inhibitor 13
  • HY-157806

    α-synuclein Neurological Disease
    α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases .
    α-Synuclein inhibitor 12
  • HY-149509

    α-synuclein Neurological Disease
    α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .
    α-Synuclein inhibitor 9
  • HY-147669

    Others Neurological Disease
    α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.95 μM and inhibition ratio at 30 μM of 85.8% .
    α-Synuclein inhibitor 7
  • HY-147666

    Others Neurological Disease
    α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 0.98 μM and inhibition ratio at 30 μM of 91.2% .
    α-Synuclein inhibitor 4
  • HY-147667

    Others Neurological Disease
    α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.22 μM and inhibition ratio at 30 μM of 94.3% .
    α-Synuclein inhibitor 5
  • HY-147668

    Others Neurological Disease
    α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.70 μM and inhibition ratio at 30 μM of 94.4% .
    α-Synuclein inhibitor 6
  • HY-147644

    Others Neurological Disease
    α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research .
    α-Synuclein inhibitor 3
  • HY-151554

    Amyloid-β Others
    SQ-3 is a quinoline analogue, displays moderate selectivity for α-syn aggregates (Ki=39.3 nM) over β-amyloid (Aβ) aggregates (Ki=230 nM). [ 18F]SQ3 has basic properties as a lead compound for the development of a useful α-syn imaging probe .
    SQ-3
  • HY-150209

    Others Neurological Disease
    MODAG-001 can bind to synuclein fibrils in a rat brain. MODAG-001 is a candidate α-syn imaging probe .
    MODAG-001
  • HY-157225

    α-synuclein Metabolic Disease
    Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease .
    Brazilin-7-acetate
  • HY-110174

    Others Neurological Disease
    NAB2 is a neuron-protective agent. NAB2 strongly and selectively protects diverse cell types from α-syn toxicity. NAB2 promots endosomal transport events dependent on the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 identifies a agentgable node in the biology of α-syn that can correct multiple aspects of its underlying pathology, including dysfunctional endosomal and endoplasmic reticulum-to-Golgi vesicle trafficking .
    NAB2
  • HY-163830

    DAD9

    Dopamine Receptor Neurological Disease
    Pegasus (DAD9) is a potent dopamine receptor agonist. Pegasus shows antioxidant and anti-inflammatory properties. Pegasus inhibits α-Syn amyloid aggregation. Pegasus has the potential for the research of Parkinson’s disease .
    Pegasus
  • HY-163739

    α-synuclein Neurological Disease
    LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies .
    LETC
  • HY-N10306

    α-synuclein Neurological Disease
    Sycosterol A is an α-synuclein (α-syn) inhibitory sterol .
    Sycosterol A
  • HY-17406S

    Ro 40-7592 d7

    Isotope-Labeled Compounds COMT Amyloid-β Neurological Disease
    Tolcapone-d7 is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].
    Tolcapone-d7
  • HY-163987

    Sirtuin Neurological Disease
    SIRT3 activator 2 (compound 2a) is a SIRT3 activator. SIRT3 activator 2 improved the thermal stability of SIRT3 in SH-SY5Y cells, indicating that it can directly bind to SIRT3, has SIRT3 dependency in SH-SY5Y to clear α-Syn. SIRT3 activator 2 improves motor function in Parkinson mice, preventing Parkinson (DA) neuron loss in the substantia nigra in a dose-dependent manner .
    SIRT3 activator 2
  • HY-149065

    α-synuclein Neurological Disease
    D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration .
    D-685
  • HY-139307

    Tau Protein Neurological Disease
    MG-2119 is a potent monomeric tau and α-syn aggregation inhibitor. MG-2119 is a potential agent for neurological disorders research .
    MG-2119
  • HY-139830

    DYRK Neurological Disease
    Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC50 = 119 nM) and the aggregation of tau and α-syn oligomers.
    Dyrk1A-IN-1
  • HY-169198

    α-synuclein Neurological Disease
    GSD-16-24 is a lead compound that binds directly to the C-terminal IDR of α-syn monomers and fibrils, thereby preventing fibrils from binding to the receptor. GSD-16-24 can be used in Parkinson's research .
    GSD-16-24
  • HY-130398

    α-synuclein Neurological Disease
    Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .
    Aerophobin-2
  • HY-161328

    Monoamine Oxidase α-synuclein Tau Protein Neurological Disease
    MAO-B-IN-31 (Compound 30) is an effective and selective inhibitor of monoamine oxidase B (monoamine oxidase B). The IC50 value is 41 nM. MAO-B-IN-31 also inhibits α-syn and tau aggregation. MAO-B-IN-31 has neuroprotective activity .
    MAO-B-IN-31
  • HY-17406
    Tolcapone
    2 Publications Verification

    Ro 40-7592

    COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .
    Tolcapone
  • HY-156435

    α-synuclein Neurological Disease
    tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein-IN-1 can be used in study Alzheimer’s disease .
    tau protein/α-synuclein-IN-1
  • HY-17406S1

    Ro 40-7592-d4

    Isotope-Labeled Compounds COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone-d4 is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver[1]. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis[2]. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma[3].
    Tolcapone-d4
  • HY-17406R

    Ro 40-7592 (Standard)

    COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone (Standard) is the analytical standard of Tolcapone. This product is intended for research and analytical applications. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .
    Tolcapone (Standard)
  • HY-101855

    Anle138b

    Amyloid-β Neurological Disease
    Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .
    Emrusolmin
  • HY-N0901A
    Corynoxine B
    3 Publications Verification

    Autophagy Beclin1 α-synuclein Neurological Disease Cancer
    Corynoxine B is a natural alkaloid and autophagy inducer that can improve Mn induced cellular autophagy dysregulation and enhance clearance of alpha synuclein (alpha syn) in Parkinson's disease mice [1][3].
    Corynoxine B
  • HY-N0901AR

    Autophagy Beclin1 α-synuclein Neurological Disease Cancer
    Corynoxine B (Standard) is the analytical standard of Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is a natural alkaloid and autophagy inducer that can improve Mn induced cellular autophagy dysregulation and enhance clearance of alpha synuclein (alpha syn) in Parkinson's disease mice .
    Corynoxine B (Standard)
  • HY-W042156

    Fungal Neurological Disease
    Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .
    Aegeline
  • HY-16009

    (+)-Phenserine; ANVS401

    Cholinesterase (ChE) Amyloid-β α-synuclein Huntingtin Neurological Disease Inflammation/Immunology
    Buntanetap ((+)-Phenserine) is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
    Buntanetap
  • HY-W042156R

    Fungal Neurological Disease
    Aegeline (Standard) is the analytical standard of Aegeline. This product is intended for research and analytical applications. Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .
    Aegeline (Standard)
  • HY-120722
    TCH-165
    1 Publications Verification

    Proteasome Cancer
    TCH-165 is a small molecule modulator of proteasome assembly, which increases 20S levels and facilitates 20S-mediated protein degradation .
    TCH-165
  • HY-123439

    Others Neurological Disease
    FTY720-C2 is a derivative of FTY72 (HY-12005). FTY720-C2 promotes the expression of brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) in multiple system atrophy (MSA) models, without causing immunosuppression. FTY720-C2 improves motor dysfunction and reduces the levels of insoluble alpha-synuclein (αSyn) in MSA mouse models. FTY720-C2 is blood-brain barrier penetrate .
    FTY720-C2
  • HY-162363

    PARP Neurological Disease
    MD6a is a melatonin derivative with inhibitroy activity towards PARP-1, which maintains proteins hemostasis and improves mitochondrial function through TOR/HSF-1 signaling. MD6a a neuroprotective effect .
    MD6a

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: